NASDAQ · STOCK
Elevance Health
$416.33
52W $273.71 – $427.19
60/100
$90.95B
17.2
0.69
Price History (6M)
Executive Summary
5 analysts weighed in with 100% agreement on a bullish lean. Growth Analyst: 3 consecutive earnings beats -- consistent execution. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily trend: uptrend.
- Daily uptrend conflicts with weekly downtrend — buying against the higher timeframe trend is higher risk.
- Higher Highs / Higher Lows structure confirms bullish price action.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
60/100
Agreement
57%
Analysts
7
Conviction
Contested
Growth Analyst
bullish
82
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 3 consecutive earnings beats -- consistent execution
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
59.6
Neutral
MACD Histogram
1.704
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$412.14
Resistance
$439.39
Bollinger %B
0.80
Inside Bands
Price vs Moving Averages
EMA 9
$411.40
Above
EMA 21
$404.48
Above
EMA 50
$389.52
Above
EMA 200
$360.68
Above
Fundamental Analysis
Valuation
93
Growth
62
Profitability
38
Financial Health
44
Valuation
P/E Ratio
17.2×
P/B Ratio
1.78×
PEG Ratio
—
Dividend Yield
1.64%
52W High
$427.19
52W Low
$273.71
Quality & Growth
ROE
1195.0%
ROA
426.0%
Gross Margin
—
Operating Margin
381.0%
Revenue Growth YoY
+944.0%
Debt / Equity
0.73
AI Fundamental Assessment
P/E ratio of 17.2 (inexpensive relative to a 15-40x range); Price-to-book of 1.8x; Revenue growth (YoY) of 9.4%; EPS growth (YoY) of -8.3%; Return on equity of 11.9%; Return on assets of 4.3%; Net margin of 2.6%; Current ratio of 0.19 (tight short-term liquidity); Debt-to-equity of 0.73; Most recent quarter beat estimates by 15.1%; 3 consecutive earnings beats; EPS growth accelerating (-44.8% -> +277.8% QoQ); Analyst estimates rising over recent quarters
Key Risks
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full ELV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile